Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ipratropium-bromide

Ipratropium-bromide Reactions 1704, p210 - 2 Jun 2018 Anisocoria: case report A 5-year-old boy developed anisocoria during treatment with ipratropium-bromide [ipratropium; dose not stated]. The boy had obstructive sleep apnea, trisomy 21, paroxysmal tonic up-gaze and moderate persistent asthma. He presented to the paediatrician with fever, increased work of breathing, cough and congestion. A diagnosis of pneumonia was made. He started receiving treatment with prednisone, salbutamol [albuterol], amoxicillin, nebulisers of ipratropium- bromide twice a day and nasal sprays of ipratropium-bromide two times a day. One week after the treatment, he developed a fixed and dilated left pupil. He was admitted to the emergency department. He was diagnosed with anisocoria without ophthalmoplegia. His right pupil 3mm to 2mm, and left pupil 5.5mm to 5mm. For sedated MRI, he was hospitalised for two days, and his results were normal. On the admission, the boy’s treatment with ipratropium- bromide was discontinued. A complete resolution of anisocoria was occurred, 48 hours after the discontinuation of ipratropium-bromide. He was discharged from the hospital. Author comment: "Anisocoria is a documented side effect of ipratropium.""Ipratropium is a muscarinic cholinergic receptor antagonist that inhibits the parasympathetic system responsible for pupillary constriction." Harer K, et al. Eye-opening etiologies. Hospital http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Ipratropium-bromide

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Download PDF
1 page

Ipratropium-bromide

Abstract

Reactions 1704, p210 - 2 Jun 2018 Anisocoria: case report A 5-year-old boy developed anisocoria during treatment with ipratropium-bromide [ipratropium; dose not stated]. The boy had obstructive sleep apnea, trisomy 21, paroxysmal tonic up-gaze and moderate persistent asthma. He presented to the paediatrician with fever, increased work of breathing, cough and congestion. A diagnosis of pneumonia was made. He started receiving treatment with prednisone, salbutamol [albuterol], amoxicillin,...
Loading next page...
1
 
/lp/springer_journal/ipratropium-bromide-D67FrxRIcP

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46853-3
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p210 - 2 Jun 2018 Anisocoria: case report A 5-year-old boy developed anisocoria during treatment with ipratropium-bromide [ipratropium; dose not stated]. The boy had obstructive sleep apnea, trisomy 21, paroxysmal tonic up-gaze and moderate persistent asthma. He presented to the paediatrician with fever, increased work of breathing, cough and congestion. A diagnosis of pneumonia was made. He started receiving treatment with prednisone, salbutamol [albuterol], amoxicillin, nebulisers of ipratropium- bromide twice a day and nasal sprays of ipratropium-bromide two times a day. One week after the treatment, he developed a fixed and dilated left pupil. He was admitted to the emergency department. He was diagnosed with anisocoria without ophthalmoplegia. His right pupil 3mm to 2mm, and left pupil 5.5mm to 5mm. For sedated MRI, he was hospitalised for two days, and his results were normal. On the admission, the boy’s treatment with ipratropium- bromide was discontinued. A complete resolution of anisocoria was occurred, 48 hours after the discontinuation of ipratropium-bromide. He was discharged from the hospital. Author comment: "Anisocoria is a documented side effect of ipratropium.""Ipratropium is a muscarinic cholinergic receptor antagonist that inhibits the parasympathetic system responsible for pupillary constriction." Harer K, et al. Eye-opening etiologies. Hospital

Journal

Reactions Weekly – Springer Journals

Published: Jun 2, 2018

There are no references for this article.